Cantor Fitzgerald Reaffirms Overweight Rating for Kura Oncology (NASDAQ:KURA)

Cantor Fitzgerald reiterated their overweight rating on shares of Kura Oncology (NASDAQ:KURA) in a report released on Thursday,Benzinga reports.

Several other brokerages also recently weighed in on KURA. JMP Securities reissued a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a report on Tuesday, November 19th. UBS Group initiated coverage on Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and decreased their target price for the stock from $26.00 to $19.00 in a report on Monday, October 14th. Finally, StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.38.

Kura Oncology Price Performance

Shares of KURA stock opened at $10.80 on Thursday. Kura Oncology has a 1-year low of $9.06 and a 1-year high of $24.17. The stock’s 50-day moving average is $17.88 and its 200 day moving average is $19.67. The company has a market cap of $839.81 million, a P/E ratio of -4.58 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in KURA. nVerses Capital LLC purchased a new stake in shares of Kura Oncology in the third quarter valued at approximately $25,000. SG Americas Securities LLC purchased a new stake in shares of Kura Oncology in the first quarter valued at approximately $110,000. Point72 DIFC Ltd purchased a new stake in shares of Kura Oncology in the third quarter valued at approximately $146,000. Quarry LP purchased a new stake in shares of Kura Oncology in the second quarter valued at approximately $196,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of Kura Oncology in the third quarter valued at approximately $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.